These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 16170462

  • 1. Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).
    Ando Y.
    Med Mol Morphol; 2005 Sep; 38(3):142-54. PubMed ID: 16170462
    [Abstract] [Full Text] [Related]

  • 2. New therapeutic approaches for familial amyloidotic polyneuropathy (FAP).
    Ando Y.
    Amyloid; 2003 Aug; 10 Suppl 1():55-66. PubMed ID: 14640043
    [Abstract] [Full Text] [Related]

  • 3. [Pathogenesis and therapy for transthyretin related amyloidosis].
    Ando Y, Jono H.
    Rinsho Byori; 2008 Feb; 56(2):114-20. PubMed ID: 18402051
    [Abstract] [Full Text] [Related]

  • 4. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
    Taguchi K, Jono H, Kugimiya-Taguchi T, Nagao S, Su Y, Yamasaki K, Mizuguchi M, Maruyama T, Ando Y, Otagiri M.
    Life Sci; 2013 Dec 18; 93(25-26):1017-22. PubMed ID: 24211615
    [Abstract] [Full Text] [Related]

  • 5. [Gene therapy in familial amyloidotic polyneuropathy by single-stranded oligonucleotides (SSOs)].
    Nakamura M, Ando Y.
    Rinsho Byori; 2004 Oct 18; 52(10):804-12. PubMed ID: 15624495
    [Abstract] [Full Text] [Related]

  • 6. Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo.
    Wei L, Kawano H, Fu X, Cui D, Ito S, Yamamura K, Ishihara T, Tokuda T, Higuchi K, Maeda S.
    Amyloid; 2004 Jun 18; 11(2):113-20. PubMed ID: 15478467
    [Abstract] [Full Text] [Related]

  • 7. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation.
    Ando Y, Terazaki H, Nakamura M, Ando E, Haraoka K, Yamashita T, Ueda M, Okabe H, Sasaki Y, Tanihara H, Uchino M, Inomata Y.
    Transplantation; 2004 Feb 15; 77(3):345-9. PubMed ID: 14966406
    [Abstract] [Full Text] [Related]

  • 8. [Therapeutic strategy for familial amyloid polyneuropathy (FAP)].
    Ikeda S.
    Rinsho Shinkeigaku; 2009 Nov 15; 49(11):953-5. PubMed ID: 20030258
    [Abstract] [Full Text] [Related]

  • 9. Antibody therapy for familial amyloidotic polyneuropathy.
    Su Y, Jono H, Torikai M, Hosoi A, Soejima K, Guo J, Tasaki M, Misumi Y, Ueda M, Shinriki S, Shono M, Obayashi K, Nakashima T, Sugawara K, Ando Y.
    Amyloid; 2012 Jun 15; 19 Suppl 1():45-6. PubMed ID: 22506915
    [Abstract] [Full Text] [Related]

  • 10. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration.
    Hou X, Aguilar MI, Small DH.
    FEBS J; 2007 Apr 15; 274(7):1637-50. PubMed ID: 17381508
    [Abstract] [Full Text] [Related]

  • 11. A transgenic rat with the human ATTR V30M: a novel tool for analyses of ATTR metabolisms.
    Ueda M, Ando Y, Hakamata Y, Nakamura M, Yamashita T, Obayashi K, Himeno S, Inoue S, Sato Y, Kaneko T, Takamune N, Misumi S, Shoji S, Uchino M, Kobayashi E.
    Biochem Biophys Res Commun; 2007 Jan 12; 352(2):299-304. PubMed ID: 17126291
    [Abstract] [Full Text] [Related]

  • 12. Gene therapy approach to FAP: in vivo influence of T119M in TTR deposition in a transgenic V30M mouse model.
    Batista AR, Gianni D, Ventosa M, Coelho AV, Almeida MR, Sena-Esteves M, Saraiva MJ.
    Gene Ther; 2014 Dec 12; 21(12):1041-50. PubMed ID: 25273354
    [Abstract] [Full Text] [Related]

  • 13. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models.
    Ferreira N, Saraiva MJ, Almeida MR.
    PLoS One; 2012 Dec 12; 7(1):e29933. PubMed ID: 22253829
    [Abstract] [Full Text] [Related]

  • 14. Familial amyloidotic polyneuropathy and transthyretin.
    Nagasaka T.
    Subcell Biochem; 2012 Dec 12; 65():565-607. PubMed ID: 23225017
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers.
    Sousa MM, Ferrão J, Fernandes R, Guimarães A, Geraldes JB, Perdigoto R, Tomé L, Mota O, Negrão L, Furtado AL, Saraiva MJ.
    Lab Invest; 2004 Jul 12; 84(7):865-73. PubMed ID: 15122304
    [Abstract] [Full Text] [Related]

  • 17. [Analyses of pathogenesis and therapeutic approaches for hereditary amyloidosis].
    Ando Y.
    Rinsho Byori; 2003 Jun 12; 51(6):530-5. PubMed ID: 12884739
    [Abstract] [Full Text] [Related]

  • 18. Liver transplantation in transthyretin-related familial amyloid polyneuropathy.
    Stangou AJ, Hawkins PN.
    Curr Opin Neurol; 2004 Oct 12; 17(5):615-20. PubMed ID: 15367866
    [Abstract] [Full Text] [Related]

  • 19. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y.
    J Clin Pharm Ther; 2014 Jun 12; 39(3):225-33. PubMed ID: 24749898
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of familial amyloid polyneuropathy].
    Adams D, Samuel D, Slama M.
    Presse Med; 2012 Sep 12; 41(9 Pt 1):793-806. PubMed ID: 22341949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.